Evidence map›Paper›PMID 25692550›Full record

ArticlePloS one2015

P2Y2R deficiency attenuates experimental autoimmune uveitis development.

Lia Judice M Relvas, Maya Makhoul, Remi Dewispelaere, Laure Caspers, Didier Communi, Jean-Marie Boeynaems, Bernard Robaye, Catherine Bruyns, François Willermain

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. P2YOral diseases · 2018
    Article
  6. The clearance of dying cells: table for two.Cell death and differentiation · 2016
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Lia Judice M RelvasDpt of Ophthalmology, CHU St-Pierre and Brugmann, Brussels, Belgium; The Institute of Interdisciplinary Research, IRIBHM, Brussels, Belgium; Université Libre de Bruxelles, Brussels, Belgium.
Maya MakhoulThe Institute of Interdisciplinary Research, IRIBHM, Brussels, Belgium; Université Libre de Bruxelles, Brussels, Belgium.
Remi DewispelaereDpt of Ophthalmology, CHU St-Pierre and Brugmann, Brussels, Belgium; The Institute of Interdisciplinary Research, IRIBHM, Brussels, Belgium; Université Libre de Bruxelles, Brussels, Belgium.
Laure CaspersDpt of Ophthalmology, CHU St-Pierre and Brugmann, Brussels, Belgium; Université Libre de Bruxelles, Brussels, Belgium.
Didier CommuniThe Institute of Interdisciplinary Research, IRIBHM, Brussels, Belgium; Université Libre de Bruxelles, Brussels, Belgium.
Jean-Marie BoeynaemsThe Institute of Interdisciplinary Research, IRIBHM, Brussels, Belgium; Dpt of Laboratory Medicine, Erasme Hospital, Brussels, Belgium; Université Libre de Bruxelles, Brussels, Belgium.
Bernard RobayeThe Institute of Interdisciplinary Research, IRIBHM, Gosselies, Belgium; Université Libre de Bruxelles, Brussels, Belgium.
Catherine BruynsThe Institute of Interdisciplinary Research, IRIBHM, Brussels, Belgium; Université Libre de Bruxelles, Brussels, Belgium.
François WillermainDpt of Ophthalmology, CHU St-Pierre and Brugmann, Brussels, Belgium; The Institute of Interdisciplinary Research, IRIBHM, Brussels, Belgium; Université Libre de Bruxelles, Brussels, Belgium.
Université Libre de Bruxelles · BECentre Hospitalier Universitaire Brugmann · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to study the role of the nucleotide receptor P2Y2R in the development of experimental autoimmune uveitis (EAU). EAU was induced in P2Y2+/+ and P2Y2-/- mice by immunization with IRBP peptide or by adoptive transfer of in vitro restimulated semi-purified IRBP-specific enriched T lymphocytes from spleens and lymph nodes isolated from native C57Bl/6 or P2Y2+/+ and P2Y2-/- immunized mice. Clinical and histological scores were used to grade disease severity. Splenocytes and lymph node cell phenotypes were analyzed using flow cytometry. Semi-purified lymphocytes and MACS-purified CD4+ T lymphocytes from P2Y2+/+ and P2Y2-/- immunized mice were tested for proliferation and cytokine secretion. Our data show that clinical and histological scores were significantly decreased in IRBP-immunized P2Y2-/- mice as in P2Y2-/- mice adoptively transfered with enriched T lymphocytes from C57Bl/6 IRBP-immunized mice. In parallel, naïve C57Bl/6 mice adoptively transferred with T lymphocytes from P2Y2-/- IRBP-immunized mice also showed significantly less disease. No differences in term of spleen and lymph node cell recruitment or phenotype appeared between P2Y2-/- and P2Y2+/+ immunized mice. However, once restimulated in vitro with IRBP, P2Y2-/- T cells proliferate less and secrete less cytokines than the P2Y2+/+ one. We further found that antigen-presenting cells of P2Y2-/- immunized mice were responsible for this proliferation defect. Together our data show that P2Y2-/- mice are less susceptible to mount an autoimmune response against IRBP. Those results are in accordance with the danger model, which makes a link between autoreactive lymphocyte activation, cell migration and the release of danger signals such as extracellular nucleotides.

Indexed as

Adoptive TransferAmino Acid SequenceAnimalsAntigen-Presenting CellsAutoimmune DiseasesCell ProliferationCytokinesEye ProteinsGene Knockout TechniquesHumansImmunizationLymph NodesMiceMolecular Sequence DataPeptide FragmentsReceptors, Purinergic P2Y2CytokinesEye ProteinsPeptide FragmentsReceptors, Purinergic P2Y2Retinol-Binding ProteinsRetinol-Binding Proteins, Interstitial

Identifiers

PMID25692550
PMCPMC4334221
OpenAlexW2016462885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.